3 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Revacept: new trials by email Literature Review of Revacept trials Research Report on Revacept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept Revacept 80 mg, Revacept 160 mg, Placebo - Stable Coronary Artery Disease | Phase 2 | Completed | Deutsches Herzzentrum Muenchen | 334 | 2017-11-20 | 2020-04-20 |
| Revacept in Symptomatic Carotid Stenosis Revacept, Placebo - Carotid Stenosis, Atherosclerosis | Phase 2 | Completed | AdvanceCor GmbH | 158 | 2013-03-08 | 2021-01-28 |
| Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion revacept (PR-15) - Thrombosis, Acute Coronary Syndrome | Phase 1 | Completed | AdvanceCor GmbH | 30 | 2006-03-01 | 2012-10-19 |
Stroke (2) · Acute Coronary Syndrome (1) · Amaurosis Fugax (1) · Atherosclerosis (1) · Carotid Stenosis (1) · Coronary Artery Disease (1) · Ischemic Attack, Transient (1) · Myocardial Infarction (1) · Thrombosis (1)
AdvanceCor GmbH (2) · Deutsches Herzzentrum Muenchen (1)
Germany (3) · United Kingdom (1)
Adnan Kastrati, MD (1) · Holger Poppert, Prof. Dr. (1) · Ian M Loftus, MD (1) · Richard Piechatzek, MD (1) · Stefanie Schuepke, MD (1) · Steffen Massberg, MD (1)